Sunil Kumar Joshi

9PUBLICATIONS

50CO-AUTHORS

Molecular targetsHaematologyGlassGene and molecular therapyGranular mechanics

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (9)

Sort by Publication Date:

|Jun 01, 2026

Dynamic genetic and nongenetic RAS pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.

|Jun 27, 2025

A reference model of circulating hematopoietic stem cells across the lifespan with applications to diagnostics.

N Furer, N Rappoport, O Milman

|Oct 10, 2023

The FLT3<sup>N701K</sup> mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib.

Sunil K Joshi, Janét Pittsenbarger, Vanessa E Kennedy

|Sep 12, 2023

Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy.

Christopher A Eide, Stephen E Kurtz, Andy Kaempf

|Feb 03, 2023

Oncoproteomic profiling of AML: moving beyond genomics.

Sunil K Joshi, Cristina E Tognon, Brian J Druker

|Mar 29, 2021

A noncanonical FLT3 gatekeeper mutation disrupts gilteritinib binding and confers resistance.

Sunil K Joshi, Setareh Sharzehi, Janét Pittsenbarger

Pageof 2

Frequent Collaborators

Jeffrey W Tyner

Brian J Druker

Shannon K McWeeney

Elie Traer

O Milman

A Lifshitz

Alexander E Perl

D Landau

N Dusaj

A Tanay

Frequent Collaborators

Jeffrey W Tyner

Brian J Druker

Shannon K McWeeney

Elie Traer